Biogen Stock Quote 1BIIB - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

209.00

Bid

206.00

Ask

206.70

Volume

0.00

0.00 Day's Range 0.00

177.65 52 Week Range 244.60

Market Cap

30.43B

Previous Close

209.00

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

145,596,895

Dividend Yield

PE Ratio

28.39

Earnings Per Share (EPS)

7.97

Revenue

9.84B

Net Profit

1.16B

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.biogen.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Biogen Inc is listed in the Biological Pds,ex Diagnstics sector of the Italian Stock Exchange with ticker 1BIIB. The last closing price for Biogen was 209.00 €. Over the last year, Biogen shares have traded in a share price range of 177.65 € to 244.60 €.

Biogen currently has 145,596,895 shares outstanding. The market capitalization of Biogen is 30.43 € billion. Biogen has a price to earnings ratio (PE ratio) of 28.39.

Biogen Completes Acquisition of Human Immunology Biosciences

Biogen Completes Acquisition of Human Immunology Biosciences CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology...

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China China is the Third Country to Launch LEQEMBI Following the United States and JapanTOKYO and CAMBRIDGE, Mass...

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union TOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen...

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease TOKYO and...

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic...

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences Transaction to include felzartamab, a potential first-in-class...

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis Development of BIIB105, an investigational antisense oligonucleotide for...

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast...

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA® CHMP positive opinion is based on a robust analytical, non-clinical and clinical data...

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy New data from the...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-8.5	-3.90804597701	217.5	220.7	209	21	217.91428571	DE
4	-4.5	-2.10772833724	213.5	220.7	209	46	215.15895197	DE
12	19.85	10.4943166799	189.15	220.7	189.05	29	208.8876087	DE
26	-17.6	-7.76699029126	226.6	229.6	177.65	32	205.55614486	DE
52	-6.6	-3.0612244898	215.6	244.6	177.65	29	207.84735833	DE
156	-6.6	-3.0612244898	215.6	244.6	177.65	29	207.84735833	DE
260	-6.6	-3.0612244898	215.6	244.6	177.65	29	207.84735833	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SERVServe Robotics Inc	$ 7.51 (185.55%)	262.73M
AUGXAugmedix Inc	$ 2.27 (147.71%)	21.87M
XCURExicure Inc	$ 0.5351 (76.02%)	14.02M
PSNLPersonalis Inc	$ 3.83 (56.33%)	22.76M
MDBHMDB Capital Holdings LLC	$ 10.675 (37.21%)	126.13k
SPWRSunPower Corporation	$ 0.6735 (-55.40%)	124.61M
HYZNHyzon Motors Inc	$ 0.149 (-47.54%)	23.63M
MEDSTRxADE Health Inc	$ 14.92 (-33.45%)	223.27k
SILOSilo Pharma Inc	$ 2.50 (-27.95%)	11.93M
KITTNauticus Robotics Inc	$ 0.0935 (-27.46%)	28.43M
SERVServe Robotics Inc	$ 7.51 (185.55%)	262.73M
NVDANVIDIA Corporation	$ 117.93 (-2.61%)	206.41M
SXTP60 Degrees Pharmaceuticals Inc	$ 0.2602 (5.77%)	202.14M
SQQQProShares UltraPro Short QQQ	$ 8.46 (2.79%)	184.21M
SPWRSunPower Corporation	$ 0.6735 (-55.40%)	119.98M